Caribou Biosciences, Inc. (CRBU)
Market Cap | 73.01M |
Revenue (ttm) | 9.99M |
Net Income (ttm) | -149.11M |
Shares Out | 93.00M |
EPS (ttm) | -1.65 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 939,776 |
Open | 0.8235 |
Previous Close | 0.8610 |
Day's Range | 0.7811 - 0.8501 |
52-Week Range | 0.7160 - 4.8500 |
Beta | 2.36 |
Analysts | Strong Buy |
Price Target | 11.80 (+1,403.19%) |
Earnings Date | May 6, 2025 |
About CRBU
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally. The company’s lead product candidate include CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma, refractory systemic lupus erythematosus, lupus nephritis, and extrarenal lupus. It also develops CB-011, a... [Read more]
Financial Performance
In 2024, Caribou Biosciences's revenue was $9.99 million, a decrease of -71.01% compared to the previous year's $34.48 million. Losses were -$149.11 million, 46.1% more than in 2023.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for CRBU stock is "Strong Buy." The 12-month stock price forecast is $11.8, which is an increase of 1,403.19% from the latest price.
News

Caribou Biosciences, Inc. (CRBU) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / April 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Caribou Biosciences, Inc. ("Caribou" or "the Company") ...

Caribou Biosciences, Inc. (CRBU) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / April 1, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Caribou Biosciences, Inc. ("Caribou" or "the Company") ...

Bronstein, Gewirtz & Grossman, LLC Is Investigating Caribou Biosciences, Inc. (CRBU) And Encourages Investors to Connect
NEW YORK, NY / ACCESS Newswire / March 30, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Caribou Biosciences, Inc. ("Caribou" or "the Company")...

Bronstein, Gewirtz & Grossman, LLC Encourages Caribou Biosciences, Inc. (CRBU) Stockholders to Inquire about Securities Investigation
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Caribou Biosciences, Inc. ("Caribou" or "the Company")...

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Caribou Biosciences, Inc. (CRBU) and Encourages Investors to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / March 25, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Caribou Biosciences, Inc. ("Caribou" or "the Company")...

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Caribou Biosciences, Inc. (CRBU) And Encourages Stockholders to Reach Out
NEW YORK, NY / ACCESS Newswire / March 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Caribou Biosciences, Inc. ("Caribou" or "the Company")...

Bronstein, Gewirtz & Grossman, LLC Is Investigating Caribou Biosciences, Inc. (CRBU) And Encourages Stockholders to Connect
NEW YORK, NY / ACCESS Newswire / March 18, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Caribou Biosciences, Inc. ("Caribou" or "the Company")...

Caribou Biosciences, Inc. (CRBU) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / March 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Caribou Biosciences, Inc. ("Caribou" or "the Company")...

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Caribou Biosciences, Inc. (CRBU) and Encourages Stockholders to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Caribou Biosciences, Inc. ("Caribou" or "the Company")...

Bronstein, Gewirtz & Grossman, LLC Encourages Caribou Biosciences, Inc. (CRBU) Investors to Inquire about Securities Investigation
NEW YORK, NY / ACCESS Newswire / March 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Caribou Biosciences, Inc. ("Caribou" or "the Company")...

Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
-- CB-010 ANTLER 2L LBCL and CB-011 CaMMouflage r/r MM Phase 1 clinical data expected in H1 2025 -- -- Advancing four clinical programs for hematologic malignancies and autoimmune diseases --

Shareholders of Caribou Biosciences, Inc. Should Contact The Gross Law Firm Before February 24, 2025 to Discuss Your Rights - CRBU
NEW YORK , Feb. 24, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Caribou Biosciences, Inc. (NASDAQ: CRBU). Shareholders who purchased shares of CRBU during th...

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Caribou To Contact Him Directly To Discuss Their Options NEW YORK CITY, NY / ACCESS N...

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of February 24, 2025 in Caribou Biosciences, Inc. Lawsuit – CRBU
NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Caribou Biosciences, Inc. (NASDAQ: CRBU).

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Caribou To Contact Him Directly To Discuss Their Options

Caribou Biosciences to Participate in Upcoming Investor Conferences
BERKELEY, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz,...

CRBU Deadline: Rosen Law Firm Urges Caribou Biosciences, Inc. (NASDAQ: CRBU) Investors to Contact the Firm for Information About Their Rights
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of securities of Caribou Biosciences, In...

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Caribou To Contact Him Directly To Discuss Their Options

Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025
-- CB-010 GALLOP Phase 1 trial initiated in lupus -- -- CB-012 AMpLify Phase 1 trial in r/r AML completes dose level 3 with no DLTs; enrolling patients at dose level 4 --

Caribou Biosciences to Present at 43rd Annual J.P. Morgan Healthcare Conference
BERKELEY, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that Rachel Haur...

Rosen Law Firm Urges Caribou Biosciences, Inc. (NASDAQ: CRBU) Investors to Contact the Firm for Information About Their Rights
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of Caribou Biosciences, Inc. (NASDAQ: CRBU) secu...

Caribou Biosciences: CB-010, chRDNA Technology Continue To Show Promise In Gene Editing
Caribou Biosciences focuses on allogeneic CAR-T therapies for hematological cancers and autoimmune diseases, leveraging its unique chRDNA genome-editing technology. In my view, CRBU's chRDNA platform ...

Caribou Biosciences Appoints Tina Albertson, MD, PhD, as Chief Medical Officer
-- Highly-experienced hematologist and oncologist with proven track record successfully driving global clinical development of CAR-T cell therapies -- BERKELEY, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) ...

Caribou Biosciences Announces Appointment of Terri Laufer, MD, to its Scientific Advisory Board
-- Dr. Laufer is an immunologist advancing the scientific understanding and treatment of autoimmune diseases -- BERKELEY, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: C...

Caribou Biosciences: Promising Gene Editing Therapies With Strong Buy Potential
Caribou Biosciences develops allogeneic therapies using CRISPR technology, focusing on hematologic cancers and autoimmune diseases. CB-010, CB-011, and CB-012 are in Phase 1 clinical trials, with CB-0...